Fahar Merchant, PhD
Dr. Merchant is a 25-year biotech veteran, a serial entrepreneur and co-founder of Medicenna. Previously he was President and CEO of Protox Therapeutics (TSX.V and TSX; now Sophiris Bio, Nasdaq) where he established a late clinical stage urology company. At Protox he raised more than $70M through multiple PIPEs, including a $35M investment by Warburg Pincus. In 1992 he co-founded IntelliGene Expressions, Inc., a biologics CDMO, and built it into one of the fastest growing companies in Canada. In 2000, by strategic in-licensing, he co-founded Avicenna Medica, Inc., a clinical stage oncology company that was sold a year later to KS Biomedix (LSE) for $90M. Fahar was CTO and Director of KS Biomedix until its acquisition by Xenova (Nasdaq and LSE; now Celtic Pharma). Fahar has closed several transactions valued at more than $300M. He has a PhD in Biochemical Engineering from Western University.
Elizabeth Williams, CPA, CA
Elizabeth Williams has more than 12 years of experience in biotech, working with publicly listed entities in both Canada and the United States. She has extensive financing experience, having played an integral role in raising more than $100 million in financing. Prior to joining Medicenna, Ms. Williams was the Vice President of Finance and Administration at Aptose Biosciences Inc. (previously Lorus Therapeutics Inc.), a biotechnology company listed on both the TSX and NASDAQ capital markets. While at Aptose, she held several positions, including Acting Chief Financial Officer during a lengthy transition period, and was responsible for a broad range of activities including financings, financial reporting and regulatory compliance. She is a CPA and CA and received a BBA from Wilfrid Laurier University.
Rosemina Merchant, MESc
Ms. Rosemina Merchant has 30 years of experience in the development of biopharmaceuticals. Most recently, Ms. Merchant was Senior VP of Development and Regulatory Affairs at Sophiris Bio (formerly, Protox Therapeutics) and responsible for development of PRX302 for prostate cancer and BPH. She transitioned PRX302, a discovery project to a late stage clinical program in less than 6 years. During that time, she executed multiple clinical trials, managed Canadian and US regulatory filings and led all CMC related outsourcing activities in the US and Europe. In 1992, Nina co-founded, IntelliGene Expressions, Inc., a biologics CDMO, where she was VP of Manufacturing and Chief Operating Officer. Nina also held a variety of senior level positions at KS Biomedix, Bioniche, GE LifeSciences, Sanof Pasteur and Alberta Innovates. Her education includes a MESc. in Biochemical Engineering from Western University.
Martin Bexon, MD
Dr. Martin Bexon, MD, has more than 15 years of experience in early and late stage clinical development including medical affairs in various therapeutic areas, particularly in oncology and hematology. He has recently worked as a strategic adviser, study medical expert and medical monitor in a number of oncology programs (U.S. and E.U.), in both solid tumors and hematological malignancies. While at CSL Behring (Bern, Switzerland) he led multiple global clinical studies across a range of indications including orphan diseases. As Global Medical Director, Dr. Bexon also led their medical affairs function for immunoglobulin products, generating more than 50% of the company’s revenues. At Hoffman-La Roche (U.K. and Switzerland) he designed and implemented multiple global clinical trials enrolling more than 10,000 subjects to support product commercialization. He has also led teams filing numerous regulatory submissions on both sides of the Atlantic and Japan. Prior to joining pharma, he practiced in the clinic as a pediatrician. He obtained his MBBS (MD equivalent) from the University of Newcastle upon Tyne, U.K.
Shafique Fidai, PhD
Shafique Fidai, PhD brings nearly 20 years of research and management experience in the biotechnology industry. Most recently, he was VP of Corporate Development at Protox Therapeutics (now Sophiris Bio) where he was part of the executive team and managed the IP portfolio and corporate transactions. Prior to Sophiris, he was at Chromos Molecular Systems and a founding member of the management team at Xenon Pharma. He has experience in strategic planning and corporate development, completing nearly $200M in partnerships, including out-licensing deals with Pfizer, Janssen Biotech, Kissei Pharma, Medimmune, Xencor, Lonza and UniQure. Shafique has a PhD in Biochemistry from Simon Fraser University.